Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized With NFKB2 Rearrangement

Recurrent Plasma Cell Myeloma Clinical Trial

Official title:

Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized With NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrangement Driven Trial, PINR)

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT02765854
• Other study ID #: IRB00077815
• Secondary ID: NCI-2016-00043MM
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: September 1, 2016
• Est. completion date: December 1, 2024

Study information

• Verified date: May 2023
• Source: Emory University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This randomized phase II trial studies how well ixazomib and dexamethasone or ixazomib, dexamethasone, and lenalidomide work based on the presence of the rearrangement of a gene called nuclear factor of kappa light polypeptide gene enhancer in B-cells 2 (NFKB2) in treating patients with multiple myeloma that has returned after a period of improvement or does not respond to treatment. Ixazomib may stop the growth of cancer cells by blocking enzymes called proteasomes needed for cell growth. Drugs used in chemotherapy, such as dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Lenalidomide may stimulate the immune system against cancer cells and may also prevent the growth of new blood vessels that tumors need to grow. It is not yet known whether ixazomib and dexamethasone, or ixazomib, dexamethasone, and lenalidomide are more effective in treating multiple myeloma.

Description:

PRIMARY OBJECTIVES: To test whether the NFKB2 rearrangement can guide the selection of treatment (ixazomib [ixazomib citrate] plus dexamethasone [Id] or ixazomib plus lenalidomide and dexamethasone [IRd]) by conducting the following comparisons: I. To compare the response rate at 4 cycles between patients treated with Id and patients treated with IRd and confirm the lack of significant difference in overall response. II. To compare the response rate at 4 cycles between non-rearranged and rearranged NFKB2 treated with Id and confirm that NFKB2 rearrangement is associated with reduce response rate. III. To compare the responses rate at 4 cycles of patients with rearranged NFKB2 treated with Id or IRd and confirm that adding lenalidomide increases the response rate in this population. SECONDARY OBJECTIVES: I. To determine time to treatment failure (TTF). II. To determine the frequency and severity of adverse events (AE) in IRd treated cohort. III. To identify novel transcribed mutations associated with Id and IRd resistance in patients with multiple myeloma (MM). IV. To determine the prevalence of NFKB2 rearrangement in relapsed/refractory MM patients screened in the study. V. To determine the prevalence of NFKB2 rearrangement according to the type of previous therapies received in all patients screened in the study. VI. To determine the toxicity profile of the study drugs according to the presence of NFKB2 rearrangement. VII. Delineate transcribed mutations associated with relapse or refractoriness to Id or IRd treatment by ribonucleic acid (RNA)-sequencing. OUTLINE: ARM A (UNMUTATED NFKB2 REARRANGEMENT): Patients receive ixazomib orally (PO) on days 1, 8, and 15 and dexamethasone PO on days 1, 8, 15, and 22. Patients with mutated NFKB2 rearrangement are randomized in to 1 of 2 treatment arms. ARM B (MUTATED NFKB2 REARRANGEMENT): Patients receive ixazomib and dexamethasone as in arm A. ARM C (MUTATED NFKB2 REARRANGEMENT): Patients receive ixazomib and dexamethasone as in arm A and lenalidomide PO daily on days 1-21. In all arms, cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients may proceed to autologous stem cell transplant after 4 cycles of treatment. After completion of study, patients are followed up monthly.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 72
• Est. completion date: December 1, 2024
• Est. primary completion date: December 1, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Voluntary written consent must be given before performance of any study related procedure not part of standard medical care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to future medical care
• Females of childbearing potential (FCBP)* must have a negative serum or urine pregnancy test with a sensitivity of at least 50 milli-International Units (mIU)/mL within 10-14 days prior to and again within 24 hours of starting lenalidomide and ixazomib and must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME, at least 28 days before she starts taking lenalidomide through 90 days after the last dose of study drug; FCBP must also agree to ongoing pregnancy testing; men must agree to use a latex condom during sexual contact with a FCBP even if they have had a vasectomy from the time of signing the informed consent form through 90 days after the last dose of study drug; in the event that the male patients choose to agree to practice true abstinence, this must follow the timelines detailed above; all patients assigned to the lenalidomide treatment group must be registered in and must comply with all requirements of the Revlimid Risk Evaluation and Mitigation Strategy (REMS) program
• *A female of childbearing potential is a sexually mature woman who:
• 1) has not undergone a hysterectomy or bilateral oophorectomy; or
• 2) has not been naturally postmenopausal for at least 24 consecutive months
• Multiple myeloma diagnosed according to standard criteria either currently or at the time of initial diagnosis
• The patient has confirmed relapsed or refractory MM
• For patients that relapse following a response to prior treatment with bortezomib or carfilzomib, six months must have elapsed since the last dose of treatment
• The patient has received 1 to 3 prior lines of therapy. By definition, a single line of therapy may consist of 1 or more agents, and may include induction, hematopoietic stem cell transplantation, and maintenance therapy. Radiotherapy, bisphosphonate, or a single short course of steroids (ie, less than or equal to the equivalent of dexamethasone 40 mg/day for 4 days) would not be considered prior lines of therapy
• Patients must have measurable disease defined by at least 1 of the following

measurements:

• Serum M-protein = 1.0 g/dL (= 10 g/L) for an immunoglobulin (Ig)G myeloma, = 0.1 g/dL for an immunoglobulin D (IgD) myeloma or 0.5 g/dL (= 5g/L) for an immunoglobulin A (IgA) myeloma
• Urine light chain = 200 mg/24 hours
• Serum free light chain = 10 mg/dL provided the free light chain (FLC) ratio is abnormal
• Patients with oligo- or non-secretory disease must have bone marrow involvement with at least 30% plasmacytosis on aspiration
• Eastern Cooperative Oncology Group (ECOG) performance status and/or other performance status 0, 1, or 2
• Absolute neutrophil count (ANC) = 1,000/mm³
• Platelet count = 75,000/mm³; in the case that platelets are between 50,000-75,000, the patient can be enrolled if the plasma cell count in the bone marrow is superior to = 50%; to meet this hematological eligibility no transfusion support and hematological growth factor are not allowed within 7 days before study enrollment
• Total bilirubin = 1.5 x the upper limit of the normal range (ULN)
• Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) = 2.5 x ULN
• Serum creatinine = 2.5 mg/dL or a calculated creatinine clearance = 50 mL/min

Exclusion Criteria:

• The patient is refractory to carfilzomib or bortezomib; (refractory is defined as patients who never achieved a response and progressed while on carfilzomib or bortezomib or within 60 days of completing treatment)
• Prior treatment with any investigational proteasome inhibitor within 6 months of study entry
• Female patients who are breast feeding or have a positive serum pregnancy test during the screening period
• Failure to have fully recovered (ie, > grade 1 toxicity) from the reversible effects of prior chemotherapy
• Diarrhea > grade 1 according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version (v)4.03
• Prior chemotherapy and/or immunotherapy within 14 days before enrollment; major surgery within 14 days before enrollment and minor surgery within 7 days prior to cycle 1 day 1
• Radiotherapy within 14 days before enrollment; if the involved field covered = 5% of the bone marrow reserve, the patient may be enrolled irrespective of the end date of radiotherapy
• Central nervous system involvement
• Infection requiring systemic antibiotic therapy or other serious infection within 14 days before study enrollment
• Evidence of current uncontrolled cardiovascular conditions, including uncontrolled hypertension, uncontrolled cardiac arrhythmias, symptomatic congestive heart failure, unstable angina, or myocardial infarction within the past 6 months
• Systemic treatment, within 14 days before the first dose of ixazomib, with strong cytochrome P450 family 3, subfamily A, polypeptide 4 (CYP3A) inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital), or use of Ginkgo biloba or St. John's wort
• Active hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positive
• Any serious medical or psychiatric illness that could, in the investigator's opinion, potentially compromise the patient's ability to understand the patient information, to give informed consent, to comply with the treatment according to this protocol or complete the study
• Diagnosed or treated for another malignancy within 2 years before study enrollment or previously diagnosed with another malignancy and have any evidence of residual disease; patients with non-melanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection
• Patient has = grade 2 peripheral neuropathy or neuropathy with pain, regardless of grade that is seen on clinical examination during the screening period
• Known intolerance to immunomodulatory drugs (IMiDs)
• History of allergic reaction/hypersensitivity to any of the study medications, their analogues or excipients in the various formulations
• Known gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of ixazomib or lenalidomide, including difficulty swallowing
• Participation in other clinical trials, including those with other investigational agents not included in this trial, such as monoclonal antibodies, within 30 days of the start of this trial and throughout the duration of this trial
• Corticosteroid doses > 10 mg/day of prednisone or equivalent within 14 days prior to cycle 1 day 1
• Autologous or allogeneic stem cell or bone marrow transplant within 3 months prior to cycle 1 day 1
• Cytotoxic therapy within 21 days prior to cycle 1 day (D) 1
• Patients that have previously been treated with ixazomib, or participated in a study with ixazomib whether treated with ixazomib or not

Related Conditions & MeSH terms

• Multiple Myeloma
• Neoplasms, Plasma Cell
• Recurrent Plasma Cell Myeloma
• Refractory Plasma Cell Myeloma

Intervention

Drug:
• Dexamethasone
Given PO
• Ixazomib
Given PO
• Lenalidomide
Given PO

Locations

Country	Name	City	State
United States	University of Michigan/Rogel Cancer Center	Ann Arbor	Michigan
United States	Emory University/Winship Cancer Institute	Atlanta	Georgia
United States	Grady Memorial Hospital	Atlanta	Georgia
United States	Washington University/Siteman Cancer Center	Saint Louis	Missouri

Sponsors (5)

Lead Sponsor	Collaborator
Emory University	Millennium Pharmaceuticals, Inc., Multiple Myeloma Research Consortium, National Cancer Institute (NCI), National Institutes of Health (NIH)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Gene expression profile	Gene expression will be associated with poor response to Id or IRd. Differential gene expression will be computed by pairwise t-tests on the variance-stabilized counts followed by correction for multiple testing using the Benjamini-Hochberg method.	Up to 30 days post-treatment
Other	Transcribed mutations via RNA-sequencing	The sequence of mutations associated with poor response to Id or IRd will compared with the mutational analysis of all samples against the results obtained from time 0.	Baseline
Primary	Response rate of very good partial response (VGPR) or better	Estimates of the complete response (CR) + VGPR rates will be presented with 2-sided 95% exact binomial confidence intervals.	At 112 days (4 cycles)
Secondary	Overall response rate (CR + VGPR + partial response [PR]), stable disease or progression	Analyzed based on the response-evaluable population. Overall response rate will be presented with 2-sided 95% exact binomial confidence interval in the subset of high-risk patients determined by cytogenetics.	At 112 days (4 cycles)
Secondary	CR, stringent CR, and VGPR rate		At 224 days (8 cycles)
Secondary	Combined CR + VGPR rate		At 224 days (8 cycles)
Secondary	PR rate		At 224 days (8 cycles)
Secondary	Time to response (TTR)	Analyzed based on the response-evaluable population. TTR will be analyzed using standard survival analysis techniques based on Kaplan-Meier estimates. TTR may also be measured in the population of patients with a confirmed response.	From the date of first dose of study treatment to the date of the first documentation of a confirmed response, assessed up to 2 years
Secondary	Duration of response (DOR)	Analyzed based on the response-evaluable population. DOR will be analyzed using standard survival analysis techniques based on Kaplan-Meier estimates.	From the date of first documentation of a confirmed response to the date of first documented progressive disease (PD), assessed up to 30 days post-treatment
Secondary	Incidence of thrombotic thrombocytopenic purpura (TTP)		From the date of first dose of study treatment to the date of first documentation of PD, assessed up to 30 days post-treatment
Secondary	Progression-free survival		From the date of first dose of study treatment to the date of first documented PD or death, assessed up to 2 years
Secondary	Incidence of adverse events	Toxicity information recorded will include the type, severity, and the probable association with the study regimen. Tables will be constructed to summarize the observed incidence by severity and type of toxicity. Additional safety analyses may be performed to most clearly enumerate rates of toxicities and to further define the safety profile of Id or IRd combinations. Treatment-emergent events will be tabulated.	Up to 30 days post-treatment